Payment overview · 2025
General Payments
$3,130.55
113 reported records · 21 companies
Healthcare provider profile · identity verified
Daniel Perez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease · PLANTATION, FL · NPI 1174594527
Verified facts
What the public records show
CMS Open Payments records show Daniel Perez, M.D. received $3,130.55 in general payments during 2025 across 113 reported records.
ViiV Healthcare Company accounted for 47.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Cabenuva, Dovato, Ozempic, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Biktarvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $1,500.07 | 47.9% | 50 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $273.11 | 8.7% | 12 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $206.49 | 6.6% | 10 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $181.16 | 5.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $165.25 | 5.3% | 6 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $148.47 | 4.7% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $115.49 | 3.7% | 5 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $83.66 | 2.7% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $78.45 | 2.5% | 4 | 2025 |
| Trilliant Surgical LLC. | Unresolved — no canonical attribution shown | $64.98 | 2.1% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.53 | 1.7% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $48.46 | 1.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.63 | 1.5% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $26.31 | 0.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.66 | 0.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.86 | 0.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.12 | 0.6% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $20.00 | 0.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.21 | 0.6% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $16.72 | 0.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.92 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,926.12 | 110 |
| Long term medical supply or device loan | $181.16 | 1 |
| Education | $23.27 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $779.85 | 25 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $263.19 | 11 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $223.17 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $206.49 | 10 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $195.25 | 8 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $181.16 | 1 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $154.40 | 5 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $148.47 | 6 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $93.34 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $78.45 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $67.51 | 3 | 2025 |
Source payment records
|
|||||
| Minimally Invasive Bunion Plate, Left Normalized: minimally invasive bunion plate left |
Device | Trilliant Surgical LLC. | $64.98 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $64.65 | 3 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $52.53 | 2 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $48.46 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.63 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $32.61 | 1 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $26.75 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| Izervay Normalized: izervay |
Drug | Astellas Pharma US Inc | $25.66 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $10.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 239 | exact normalized | Medicare Part D |
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 113 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 26 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
239 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 24 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
113 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 239 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 157 | 42 |
| Atorvastatin Calcium | Atorvastatin Calcium | 156 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 154 | 47 |
| Juluca | Dolutegravir/Rilpivirine | 123 | 15 |
| Dovato | Dolutegravir Sodium/Lamivudine | 113 | 15 |
| Losartan Potassium | Losartan Potassium | 100 | 29 |
| Alprazolam | Alprazolam | 98 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 80 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 22 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 68 | suppressed |
| Metformin Hcl | Metformin Hcl | 67 | 17 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 63 | 63 |
| Cabenuva | Cabotegravir/Rilpivirine | 54 | suppressed |
| Lisinopril | Lisinopril | 54 | 13 |
| Omeprazole | Omeprazole | 52 | 16 |
| Simvastatin | Simvastatin | 49 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 26 |
| Gabapentin | Gabapentin | 42 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 15 |
| Azithromycin | Azithromycin | 38 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 15 |
| Eliquis | Apixaban | 36 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 11 |
| Montelukast Sodium | Montelukast Sodium | 34 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 34 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 16 |
| Ozempic | Semaglutide | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 26 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Carvedilol | Carvedilol | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 17 |
| Irbesartan | Irbesartan | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 12 |
| Valsartan | Valsartan | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Crestor | Rosuvastatin Calcium | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Niacin Er | Niacin | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 14 | 14 |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Tivicay | Dolutegravir Sodium | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Famotidine | Famotidine | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,130.55 · 113 records | ViiV Healthcare Company | APRETUDE, AVYCAZ, Arikayce, Biktarvy, CABENUVA, CAPVAXIVE, Cologuard Collection Kit, DALVANCE, DOVATO, EMBLAVEO, FLUZONE HIGH-DOSE, Fluad, Flucelvax, Integra, Izervay, LEQVIO, Minimally Invasive Bunion Plate, Left, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PAXLOVID, PIFELTRO, Quviviq, REPATHA, RUKOBIA, The Cologuard Plus Collection Kit, VOWST, XIFAXAN, Xhance, ZENPEP, ZEPBOUND, ZERBAXA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error